<DOC>
	<DOCNO>NCT02718144</DOCNO>
	<brief_summary>This multi-center , open-label , phase I/IIa trial , dose-escalation study 3 + 3 cohort design determine recommend dose estetrol treatment patient advance breast cancer . After complete phase I part study ( i.e . 4 week treatment ) , patient receive treatment 8 week individual phase I dose level ( phase IIa part study ) .</brief_summary>
	<brief_title>Assessment Safety Efficacy Estetrol Postmenopausal Women With Advanced Estrogen Receptor Positive ( ER+ ) Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Postmenopausal woman ERpositive HER2negative locally advance and/or metastatic breast cancer , progress standard therapy standard therapy intolerant ; Patients experience natural surgical menopause least 5 year ago ; Failure antiestrogen treatment tamoxifen aromatase inhibitor ( ) due development resistance unacceptable side effect treatment ; No undiagnosed vaginal bleeding ; No treatment fulvestrant within 6 month start treatment ; Life expectancy least 6 month ; Tumour assessment ( CT scan ) within 28 day start E4 treatment ; Body mass index ( BMI ) ( ≥ ) 18 ( ≤ ) 35 kg/m2 ; Able swallow oral medication ; Acceptable value hematological parameter , liver kidney function calcium level ; Reasonable physical mental health judge investigator determine physical examination , clinical laboratory assessment vital sign ; Willing give informed consent writing . Uncontrolled nausea , vomit , diarrhea ; History venous arterial thromboembolic disease know defect blood coagulation system ; Uncontrolled hypertension , i.e . systolic blood pressure 160 mmHg and/or diastolic blood pressure 100 mmHg last 6 month without medication ; Diabetes mellitus poor glycaemic control last 6 month ( HbA1c 7.5 % ) ; Any serious disease include systemic lupus erythematosus untreated cholelithiasis ; Smoking &gt; 10 cigarettes/day ; Use cancer therapy include radiotherapy ( except palliative reason ) , endocrine therapy , immunotherapy , chemotherapy , use investigational agent start treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>dose-escalation</keyword>
	<keyword>safety</keyword>
	<keyword>dose-limiting toxicity</keyword>
</DOC>